FEB 21, 2018 6:00 AM PST

Using HDAC Inhibitors to Improve Cancer Immunotherapy

Presented at: Drug Discovery 2018
Speaker

Abstract

We recently reported that HDAC6 is involved in the regulation of a number of immunosuppressive checkpoint proteins, including the Program Death Receptor Ligand 1 (PD-L1). This protein is one of the natural ligands for the PD-1 receptor present on T-cells, consistently reported to suppress T-cell activation, proliferation, and induce T-cell exhaustion, anergy and apoptosis. As a result, increased PD-L1 expression by cancer cells remains a fundamental escape mechanism from host immunity within the tumor microenvironment, and the understanding the molecular mechanisms modulating PD-L1 and other immunosuppressive mediators could lead to improved treatments for cancer patients. Several publications have linked the over-expression of PD-L1 in tumors and tumor microenvironment with a poor prognosis in several malignancies, including melanoma, ovarian, gastric and breast cancer, among many others. However, more detailed mechanistic information regarding the molecular events involved in the regulation of PD-L1 is still missing. Moreover, limited information is available about the participation of preclinical and clinical anti-cancer agents in the regulation of PD-L1 and other immunomodulatory pathways. As a result, this gap in knowledge is preventing the design of new immunotherapeutic combination therapies. Given the fact that HDAC6 is a potential regulator of immunosuppressive mediators, it opens up a new avenue for immunotherapy. By using selective HDAC6inh as adjuvants to ongoing immune blockade based treatments, we are aiming to further augment anti-tumor immune responses.   


Show Resources
You May Also Like
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
OCT 13, 2021 7:00 AM PDT
C.E. CREDITS
OCT 13, 2021 7:00 AM PDT
Date: October 13, 2021 Time: 7:00am (PDT), 10:00am (EDT) Western blot analysis is a method widely used in the lab today because of its versatility in detecting and measuring specific target...
JUL 15, 2021 8:00 AM PDT
C.E. CREDITS
JUL 15, 2021 8:00 AM PDT
Date: July 15, 2021 Time: 8:00am (PDT), 11:00am (EDT) High dimensional full spectrum flow cytometry grants unprecedented access to previously unattainable parameters in cellular biology. Flu...
OCT 14, 2021 9:00 AM PDT
C.E. CREDITS
OCT 14, 2021 9:00 AM PDT
Date: October 14, 2021 Time: 9:00am (PDT), 12:00pm (EDT), 5:00pm GMT Western blot analysis is a method widely used in the lab today because of its versatility in detecting and measuring spe...
FEB 21, 2018 6:00 AM PST

Using HDAC Inhibitors to Improve Cancer Immunotherapy

Presented at: Drug Discovery 2018

Specialty

Immuno-Oncology

Health

Research And Development

Regulatory Affairs

Marketing

Earth Science

University

Fda

Pharmaceutical

Research

Prescription Drug

Cancer

Geography

North America50%

Asia50%

Registration Source

Website Visitors100%

Job Title

Student50%

Medical Laboratory Technician50%

Organization

Academic Institution50%

Manufacturer - Other50%


Show Resources
Loading Comments...
Show Resources